Pharmaceutical News

RSS

Too much folic acid during pregnancy puts daughters at risk of diabetes, obesity later in life

Mothers that take excessive amounts of folic acid during pregnancy may predispose their daughters to diabetes and obesity later in life, according to a new study published today in the Journal of Endocrinology. With high dose supplements being widely available, the study calls for a need to establish a safe upper limit of folic acid intake for pregnant women.

10 Feb 2015

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis Pharmaceuticals, Inc. announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders.

10 Feb 2015

HPV vaccine does not increase rates of STIs in adolescent females

Receiving the human papillomavirus vaccine does not increase rates of sexually transmitted infections (STIs) in adolescent females. The vaccine, which can prevent cervical cancer in women, has had a low uptake, partly because of concerns about how it will affect adolescent sexual activity.

10 Feb 2015

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia.

10 Feb 2015

Psychedelic drug prevents allergic asthma in mouse model

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model.

10 Feb 2015

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

10 Feb 2015

Drug similar to Gleevec may help tame some brain cancers

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth.

10 Feb 2015

Mice genetically deficient in serotonin are more vulnerable to social stressors

Mice genetically deficient in serotonin -- a crucial brain chemical implicated in clinical depression -- are more vulnerable than their normal littermates to social stressors, according to a Duke study appearing this week in the Proceedings of the National Academy of Sciences.

10 Feb 2015

New study shows that chronic narcotic use more prevalent in children with IBD

Chronic narcotic use is more than twice as prevalent in children with inflammatory bowel disease (IBD), compared with children without this disease, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

10 Feb 2015

Combination therapies may overcome resistance to targeted cancer drugs

A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.

10 Feb 2015

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.

10 Feb 2015

Cohera Medical gets FDA approval to distribute TissuGlu Surgical Adhesive in US

Cohera Medical, Inc.®, a leading innovator and developer of surgical adhesives and sealants, announced today that the U.S. Food and Drug Administration (FDA) has approved its TissuGlu® Surgical Adhesive.

9 Feb 2015

New AGA guideline provides guidance to prevent HBV reactivation

Long-term immunosuppressive therapy can cause the hepatitis B virus (HBV) to become active, even in patients who are not aware that they are infected with the virus. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others.

9 Feb 2015

Study explores effects of medical marijuana in children and teens with ASD, ADHD

As medical marijuana becomes increasingly accepted, there is growing interest in its use for children and adolescents with developmental and behavioral problems such as autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD), according to a review in the February Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics.

9 Feb 2015

Salicylates drugs reduce proliferation, viability of cultured vestibular schwannoma cells

Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

9 Feb 2015

Confidence in government may play key role in public's willingness to take swine flu vaccine

A new study suggests that confidence in government may play a key role in the public's willingness to get at least some vaccine

9 Feb 2015

Added benefit of lurasidone drug not proven for schizophrenia

The drug lurasidone (trade name Latuda) has been available since November 2014 for the treatment of adults with schizophrenia. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

8 Feb 2015

American Osteopathic Association reiterates support for CDC vaccination protocols

Amid continuing outbreaks of preventable illnesses, the American Osteopathic Association reiterated its support for CDC vaccination protocols and cited the importance of a fully vaccinated population on the public health of the nation.

7 Feb 2015

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

At the "Symposium on the Application of Genetic Testing in Individualized Diagnosis and Treatment of Tumor" recently held in Tianjin, the research team led by Professor Hao Jihui of the Pancreas Oncology Department of Tianjin Medical University Cancer Hospital announced that they had achieved a major breakthrough in the field of nano-carrier drugs for pancreatic cancer.

6 Feb 2015

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

6 Feb 2015

Pharmaceutical News

Too much folic acid during pregnancy puts daughters at risk of diabetes, obesity later in life

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

HPV vaccine does not increase rates of STIs in adolescent females

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Psychedelic drug prevents allergic asthma in mouse model

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

Drug similar to Gleevec may help tame some brain cancers

Mice genetically deficient in serotonin are more vulnerable to social stressors

New study shows that chronic narcotic use more prevalent in children with IBD

Combination therapies may overcome resistance to targeted cancer drugs

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Cohera Medical gets FDA approval to distribute TissuGlu Surgical Adhesive in US

New AGA guideline provides guidance to prevent HBV reactivation

Study explores effects of medical marijuana in children and teens with ASD, ADHD

Salicylates drugs reduce proliferation, viability of cultured vestibular schwannoma cells

Confidence in government may play key role in public's willingness to take swine flu vaccine

Added benefit of lurasidone drug not proven for schizophrenia

American Osteopathic Association reiterates support for CDC vaccination protocols

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

Chemotherapy or immunosuppressive treatment may reactivate HBV

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News